Published in Int J Radiat Oncol Biol Phys on February 03, 2010
Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: implications for prostate brachytherapy. Brachytherapy (2012) 2.05
Prostate cancer: prediction of biochemical failure after external-beam radiation therapy--Kattan nomogram and endorectal MR imaging estimation of tumor volume. Radiology (2011) 1.44
Overlooking evolution: a systematic analysis of cancer relapse and therapeutic resistance research. PLoS One (2011) 1.32
Tumor focality in prostate cancer: implications for focal therapy. Nat Rev Clin Oncol (2010) 1.09
Impact of intraoperative MRI/TRUS fusion on dosimetric parameters in cT3a prostate cancer patients treated with high-dose-rate real-time brachytherapy. J Contemp Brachytherapy (2014) 0.81
Evaluation of 3 T pelvic MRI imaging in prostate cancer patients receiving post-prostatectomy IMRT. World J Urol (2014) 0.77
The accuracy of magnetic resonance imaging in radical prostatectomy. Curr Urol (2013) 0.75
Disparities in staging prostate magnetic resonance imaging utilization for nonmetastatic prostate cancer patients undergoing definitive radiation therapy. Adv Radiat Oncol (2016) 0.75
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys (2006) 11.17
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA (2005) 8.72
A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst (1998) 8.33
Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol (2003) 4.66
Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst (2006) 4.14
Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol (2002) 3.61
Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol (2007) 3.12
Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology (2006) 2.49
Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging--clinicopathologic study. Radiology (1999) 2.32
Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology (2005) 1.82
Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology (1999) 1.82
Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol (2000) 1.80
The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int (2007) 1.71
Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging--initial results. Radiology (2007) 1.67
Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse. Clin Prostate Cancer (2004) 1.55
Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume. Radiology (2009) 1.55
Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol (2002) 1.50
Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging: multivariate feature analysis. Radiology (1997) 1.43
Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer. J Urol (2005) 1.42
Planning, delivery, and quality assurance of intensity-modulated radiotherapy using dynamic multileaf collimator: a strategy for large-scale implementation for the treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys (1997) 1.42
Predicting outcomes in prostate cancer: how many more nomograms do we need? J Clin Oncol (2007) 1.36
Prostate cancer: detection of extracapsular extension by genitourinary and general body radiologists at MR imaging. Radiology (2004) 1.30
Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging to the Kattan nomogram. Radiology (2006) 1.24
Prostate cancer: incremental value of endorectal MR imaging findings for prediction of extracapsular extension. Radiology (2004) 1.21
Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer. J Urol (2000) 1.20
Endorectal MR imaging in the evaluation of seminal vesicle invasion: diagnostic accuracy and multivariate feature analysis. Radiology (2006) 1.14
Per-sextant localization and staging of prostate cancer: correlation of imaging findings with whole-mount step section histopathology. AJR Am J Roentgenol (2007) 1.11
Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials. J Clin Oncol (2000) 1.07
Pretreatment endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging features of prostate cancer as predictors of response to external beam radiotherapy. Int J Radiat Oncol Biol Phys (2008) 1.05
Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer. Urology (2007) 1.04
Prostate cancer: role of pretreatment MR in predicting outcome after external-beam radiation therapy--initial experience. Radiology (2008) 0.99
Magnetic resonance imaging in the prediction of biochemical recurrence of prostate cancer after radical prostatectomy. BJU Int (2009) 0.93
Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. Cancer (1997) 0.92
Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer. AJR Am J Roentgenol (2006) 0.91
Local staging of prostate carcinoma with endorectal coil MRI: correlation with whole-mount radical prostatectomy specimens. Eur Radiol (1996) 0.88
Quantifying the impact of seminal vesicle invasion identified using endorectal magnetic resonance imaging on PSA outcome after radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys (2004) 0.85
Preliminary results of a bone marrow magnetic resonance imaging protocol for patients with high-risk prostate cancer. Urology (1999) 0.80
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
A randomized prospective multicenter trial of pancreaticoduodenectomy with and without routine intraperitoneal drainage. Ann Surg (2014) 7.08
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol (2012) 4.21
The pulvinar regulates information transmission between cortical areas based on attention demands. Science (2012) 4.14
Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med (2010) 4.11
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA (2004) 4.10
Persisters: a distinct physiological state of E. coli. BMC Microbiol (2006) 4.03
Altered functional connectivity in early Alzheimer's disease: a resting-state fMRI study. Hum Brain Mapp (2007) 3.92
High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys (2008) 3.78
Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol (2010) 3.76
The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s. Health Econ (2005) 3.61
Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol (2010) 3.49
Uncovering intrinsic modular organization of spontaneous brain activity in humans. PLoS One (2009) 3.43
Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J (2002) 3.27
Genome-wide association scans identified CTNNBL1 as a novel gene for obesity. Hum Mol Genet (2008) 3.24
Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol (2012) 3.20
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nat Med (2012) 2.95
Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54. Nat Genet (2010) 2.95
Regional coherence changes in the early stages of Alzheimer's disease: a combined structural and resting-state functional MRI study. Neuroimage (2007) 2.94
Parcellation-dependent small-world brain functional networks: a resting-state fMRI study. Hum Brain Mapp (2009) 2.91
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation. Proc Natl Acad Sci U S A (2009) 2.86
The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell (2012) 2.84
Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol (2007) 2.83
Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer (2005) 2.78
Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline. J Urol (2013) 2.76
Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys (2005) 2.75
Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology (2005) 2.71
Improving communication of diagnostic radiology findings through structured reporting. Radiology (2011) 2.69
Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol (2007) 2.69
Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol (2003) 2.67
Kir6.2 is required for adaptation to stress. Proc Natl Acad Sci U S A (2002) 2.60
Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys (2003) 2.58
Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer. Urology (2010) 2.57
Caution on pedigree haplotype inference with software that assumes linkage equilibrium. Am J Hum Genet (2002) 2.51
Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology (2005) 2.49
Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol (2012) 2.45
TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res (2009) 2.42
Regional homogeneity changes in patients with Parkinson's disease. Hum Brain Mapp (2009) 2.42
Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer (2010) 2.42
Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology (2006) 2.40
Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov (2012) 2.39
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A (2007) 2.37
Fluoroscopically guided interventional procedures: a review of radiation effects on patients' skin and hair. Radiology (2010) 2.36
A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol (2013) 2.33
Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med (2011) 2.33
Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer (2009) 2.32
Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation. Am J Surg Pathol (2009) 2.32
Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol (2008) 2.30
Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics (2013) 2.27
Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res (2013) 2.26
Distribution of renal tumor growth rates determined by using serial volumetric CT measurements. Radiology (2009) 2.24
Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology (2013) 2.24
Prognostic significance of location of positive margins in radical prostatectomy specimens. Urology (2007) 2.23
Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations. Radiology (2013) 2.21
Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol (2007) 2.20
Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov (2013) 2.15
Genome-wide association and follow-up replication studies identified ADAMTS18 and TGFBR3 as bone mass candidate genes in different ethnic groups. Am J Hum Genet (2009) 2.14
Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology (2004) 2.13
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A (2007) 2.11
Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology (2011) 2.10
High-risk prostate cancer: from definition to contemporary management. Eur Urol (2012) 2.06
Management of low grade papillary bladder tumors. J Urol (2007) 2.04
BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res (2008) 2.03
Prognostic immune markers in non-small cell lung cancer. Clin Cancer Res (2011) 2.03
American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy (2012) 2.03
Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discov (2011) 2.02
Default mode network as revealed with multiple methods for resting-state functional MRI analysis. J Neurosci Methods (2008) 2.01
Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol (2011) 2.01
The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes (2010) 2.00
Tumor size is associated with malignant potential in renal cell carcinoma cases. J Urol (2009) 1.98
Urothelial carcinoma of the renal pelvis: a clinicopathologic study of 130 cases. Am J Surg Pathol (2004) 1.97
Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol (2006) 1.97
Local disease control for spinal metastases following "separation surgery" and adjuvant hypofractionated or high-dose single-fraction stereotactic radiosurgery: outcome analysis in 186 patients. J Neurosurg Spine (2013) 1.96
Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet (2003) 1.96
Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol (2004) 1.95
Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. Cancer Res (2006) 1.94
Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol (2013) 1.92
Salvage re-irradiation for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys (2007) 1.91
Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma. J Urol (2009) 1.91
Intensity-modulated radiation therapy: supportive data for prostate cancer. Semin Radiat Oncol (2008) 1.91
Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol (2002) 1.90
Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy. J Clin Oncol (2008) 1.89
Solid renal cortical tumors: differentiation with CT. Radiology (2007) 1.87